IP Library Granted Patent US 9,139,877
Granted Patent B2
US 9,139,877 · App. 13/707,383 · Granted Sep 22, 2015

Macrophage migration inhibitory factor (MIF) promoter polymorphism in inflammatory disease

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,139,877
App. No.
13/707,383
Granted
Sep 22, 2015
Kind
B2
Abstract

Describe herein is a novel CATT-tetranucleotide repeat polymorphism at position −817 of the human Mif that functionally affects the activity of the Macrophage Inhibitory Factor (MIF) promoter in gene reporter assays. Four genotypes are described which comprise 5, 6, 7, or 8-CATT repeat units. Of these, the 5-CATT allele has the lowest level of basal and stimulated MIF promoter activity in vitro. The presence of the low expressing, 5-CATT repeat allele correlated with low disease severity in a cohort of rheumatoid arthritis patients. Methods, compositions and apparatus for detecting this CATT-tetranucleotide repeat polymorphism at position −817 of the human Mif gene, and for using same for assessing predisposition to severe inflammatory disease, are also disclosed.

Claims (11)

1. An in vitro method for diagnosing severity of or screening for severity of rheumatoid arthritis in a patient with rheumatoid arthritis, comprising:

a) amplifying CATT repeat units that begin at nucleotide position 259 of the human MIF gene (SEQ ID NO: 12) with a PCR primer amplification set,

b) analyzing the size of the amplified product to determine how many CATT repeats are present, and

c) detecting the presence or absence of homozygous 5,5 CATT repeat units that begin at nucleotide position 259 of SEQ ID NO: 12,

wherein the primer amplification set comprises a set of primers selected from the group consisting of SEQ ID NO: 1 and SEQ ID NO: 2, SEQ ID NO: 1 and SEQ ID NO: 9, and SEQ ID NO: 10 and SEQ ID NO: 11, and

wherein the presence of a homozygous 5,5 CATT genotype indicates diagnosis of, or is associated with, a lower risk of severe arthritis, and

wherein the absence of a homozygous 5,5, CATT genotype indicates diagnosis of, or is associated with, a higher risk of severe arthritis.

2. A method of amplifying the CATT repeat units that begin at position 259 of SEQ ID NO: 12 in a DNA containing sample from a patient with rheumatoid arthritis, comprising:

a) amplifying the CATT repeat units with a PCR primer amplification set, and

b) analyzing the size of the amplified product to determine the presence or absence of five CATT repeats,

wherein the primer amplification set comprises a set of primers selected from the group consisting of SEQ ID NO: 1 and SEQ ID NO: 2, SEQ ID NO: 1 and SEQ ID NO: 9, and SEQ ID NO: 10 and SEQ ID NO: 11.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 17, 2015
From: BAXTER HEALTHCARE SA
To: BAXALTA GMBH; BAXALTA INCORPORATED
Reel/Frame 036379/0331 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 17, 2015
From: BAXTER INTERNATIONAL INC.
To: BAXALTA GMBH; BAXALTA INCORPORATED
Reel/Frame 036371/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 13, 2013
From: BAUGH, JOHN A.; BUCALA, RICHARD; CHITNIS, SMITA; DONNELLY, SEAMUS C.; GREGERSEN, PETER K.; MONTEIRO, JOANITA
To: CYTOKINE PHARMASCIENCES, INC.
Reel/Frame 030604/0553 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 13, 2013
From: CYTOKINE PHARMASCIENCES, INC.
To: BAXTER INTERNATIONAL INC.; BAXTER HEALTHCARE S.A.
Reel/Frame 030604/0629 →